The following are publications of note from liver health experts and relate to the need for better biomarkers — and improved testing methods for hepatic impairment — to support therapeutic development and optimal patient care:

• April 29, 2019 — Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations from the Liver Forum.  Cheung A, et al, for The Liver Forum Case Definitions Working Group. Hepatology 2019; ePub prior to publication.

• Gastroenterology 2017;153:621–625 — Baseline Parameters in Clinical Trials For Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum

• 2014 – Challenges and Opportunities in Drug and Biomarker Development for NASH: Findings and Recommendations from an American Association for the Study of Liver Diseases (AASLD) – Food and Drug Administration (FDA) Joint Workshop (2014)